Tag Archives: prostate cancers

Breathalyser to detect disease

Scientists at the University of Wisconsin-Madison have developed a simple way of testing the air we breathe out to see whether we might be in the early stages of a number of diseases.

Illnesses including cancer, diabetes and infections change our metabolism in different ways. This research, published in the journal Metabolism, shows that it’s possible to detect these biochemical changes very early on in the development of a disease, perhaps within a few hours. This could mean that in future we could start treatment very much earlier.

“With this methodology we have advanced methods for tracing metabolic pathways that are perturbed in disease,” says senior author Fariba Assadi-Porter from the Nuclear Magnetic Resonance Facility at Madison. “It’s a cheaper, faster and more sensitive method of diagnosis.”

At the moment research is still in its early stages. The scientists have been studying mice that have metabolic symptoms similar to those found in women with polycystic ovary syndrome, a condition that may take a range of tests and examinations to diagnose.

“The goal is to find a better way of diagnosing these women early on, before puberty, when the disease can be controlled by medication or exercise and diet, and to prevent these women from getting metabolic syndromes like diabetes, obesity and associated problems like heart disease,” Assadi-Porter says.

The results showed that changes in the ratio of different elements in the animals’ breath could be detected almost instantly. This is important because the pattern of these ratios in blood or breath is different for different diseases – for example cancer, diabetes, or obesity – which means that this method could be used to detect a wide range of diseases,

Breathalyser

Breathalyser

Our bodies use different sources to provide us with energy, depending on our condition. “Your body changes its fuel source. When we’re healthy we use the food that we eat,” says Assadi-Porter. “When we get sick, the immune system takes over the body and starts tearing apart proteins to make antibodies and use them as an energy source.”

In other words, when we’re not well our bodies use proteins to keep us running instead of sugars. And this means that our bodies use different biochemical pathways. The end result is that what we breathe out is different when we’re ill.


Making it easier to detect illness earlier could make a big difference to our health. As Diabetes UK points out, the earlier this condition is diagnosed, the better. However, half the people with Type 2 diabetes are already showing signs of complications by the time they find out they have it. Complications may begin five to six years before diagnosis, and the diabetes may have begun 10 years or more before it is finally diagnosed.

Perhaps one day we’ll be able to pick up a metabolic breathalyser along with our toothpaste, but that is still some way off. The scientists who carried out this research have set up a company to develop the technology. As well as aiding diagnosis, they feel that it could tell us very quickly how effective a treatment is.

This isn’t the first research of this kind. Last year a study published in the British Journal of Cancer talked about an ‘electronic nose’ that could tell the difference between the molecules in the breath of people with head and neck cancer and that of healthy people. In 2010 early results from another study, carried out with people with lung, breast, bowel and prostate cancers also showed promising results.

There have even been small studies looking at whether dogs can tell the difference between the breath or urine of healthy people and those with cancer. The results were mostly positive, but a lot more research needs to be carried out before man’s best friend earns a white coat and a stethoscope.

New Prostate Cancer screening test

Novel PSA velocity (PSAV) risk count testing may provide a more effective way for physicians to screen men for clinically significant prostate cancer, a new study by NYU Langone Medical Center and Northwestern University Feinberg School of Medicine has revealed.

The new study, published online by the British Journal of Urology International on February 1, 2012, shows the benefits of tracking a man’s PSA levels over time to help doctors more accurately assess his risk of life-threatening prostate cancer.

“Risk count could represent a new way to screen for prostate cancer by focusing on men with the greatest risk of harmful prostate cancers,” said lead author Stacy Loeb, MD, an urologist in the Department of Urology and the Joel E. Smilow Comprehensive Prostate Cancer Center at NYU Langone. “The goal of risk count is to help identify the aggressive, clinically significant prostate cancers before advanced symptoms develop, while decreasing the diagnosis of insignificant cancers.”

Prostate cancer is the second leading cause of cancer death in American men, with an estimated 1 in 6 men diagnosed with the disease during their lifetime. Prostate cancer does not present symptoms until advanced stages so screening for the disease is vital. Currently, a PSA blood test is the standard screening method to evaluate a man’s risk of prostate cancer. It measures the amount of prostate-specific antigen in the blood, a substance made only in the prostate gland. An elevated PSA can indicate the presence of disease. However, PSA can also be elevated with benign prostate enlargement and one high PSA value does not always mean an aggressive prostate cancer is present.

prostate cancer

Prostate cancer

The new PSAV risk count screening works by monitoring fluctuations in PSA levels over time to analyze a man’s risk of prostate cancer, instead of relying on just one PSA test result to assign prostate cancer risk. The risk count is calculated by counting the number of times in a row that the PSA level in the blood increases by 0.4 ng/mL. If PSA goes up by more than 0.4 units multiple years in a row, the risk count rises indicating the patient has an increased risk of aggressive prostate cancer. For example, a man who has a PSA screening for two years in a row would be given a “2″ risk count if his serial PSA velocity measurements increased by more than 0.4 units, a “1″ risk count if there was only one increase by more than 0.4 units, and a “0″ risk count if there was no increase by more than 0.4 units.


In the study, researchers showed PSAV risk count could improve the specificity of screening for prostate cancer and advanced stages of the disease. Researchers evaluated 18, 214 men undergoing prostate cancer screening, 1,125 of which were diagnosed with the disease. The study results show sustained rises in PSA levels over time indicate a significantly greater risk of prostate cancer and more aggressive disease. In the study, a risk count of “2″ was associated with a greater than 8-times risk of prostate cancer and a 5-fold greater risk of aggressive disease. The authors conclude risk count screening may be useful in diagnosing aggressive prostate cancer earlier while possibly reducing unnecessary biopsy, as well as the overdiagnosis and resulting overtreatment of low-risk prostate cancer.

“A persistently rising PSA is a harbinger for life-threatening prostate cancer,” said the study’s senior author, William Catalona, MD, professor of Urology at Northwestern University. “Our study findings show looking at how much PSA changes over time helps distinguish which cancers are aggressive more so than a single PSA value.”

In an accompanying editorial, Dr. H. Ballentine Carter from the Brady Urological Institute at Johns Hopkins who initially suggested the concept of looking at PSA changes over time, affirms that in order to determine the likelihood of aggressive prostate cancer, “you want to know your patient’s risk count, not just their age and PSA level.”